Lipid Profile in HIV Infected Children Receiving Antiretroviral Treatment

Dr. Kavita J. Lall1, Dr. Omesh Khurana2, Dr. Ranjit S Ambad3

1Associate Professor Department of Pediatrics CCM Medical College, Kachandur, Durg (CG)
2Assistant Professor Department of Pediatrics CCM Medical College, Kachandur, Durg (CG)
3Assistant Professor Dept. of Biochemistry CCM Medical College, Kachandur, Durg (CG)

Abstract:
This study reviewed the lipid profile of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients in relation to use of antiretroviral therapy (ART). Lipid profile is becoming one of the common problems in human immunodeficiency virus infected patients receiving antiretroviral therapy. Data on lipid profile derangements induced by antiretroviral treatment. The aim of this study was to assess the lipid profile abnormalities in HIV infected children receiving ART. Material and Method - Information on sex, age, specific ART type in use, ART start date, duration of treatment, duration of HIV infection, BMI, relevant signs and symptoms and medications if any were collected by trained nurses using structured questionnaires and patients medical record. Blood Sample Collection, Transport and Processing - Following a standard and safety collection procedure, about 5 ml fasting venous blood was taken from the patients and the control groups by clinical nurses and senior laboratory technologist. Fasting serum samples were analyzed for total cholesterol (TC), triglyceride (TG), High Density Lipoprotein-Cholesterol (HDL-c). Low density lipoprotein cholesterol (LDL) and Very low density lipoprotein (VLDL) was determined by Friedewald Equation (13). Result and conclusion - There was statistically significant difference between the two groups for TC, TG, TC/HDL-c ratio and TG/HDL–c ratio. On the basis of our study we concluded that the level of TG, TC, HDL-c and VLDL-c is high in HIV positive populations receiving first line ART (group I) as compared to ART naïve (group II). Considering that these altered lipid profiles can be an independent risk factors for coronary artery diseases and myocardial infarction, treatment with first-line ART may actually have potential risks for cardiovascular health of HIV positive people receiving ART.

Keywords - ART, HIV, TC, TG, LDL-c, HDL-c, VLDL-c, AIDS and CD4

Introduction
All HIV-infected children reach a point in their disease when they need antiretroviral treatment. Good nutritional care and support remains important if the child is to benefit optimally from ART. Most antiretroviral drugs do not need specific recommendations in relation to meals/foods, while some should not be taken with meals or with specific foods e.g. saquinavir and garlic. Although some antiretroviral drugs can lead to late complications such as anaemia, lipodystrophy, and diabetes these can generally be managed and ART continued. Overall the benefits of ART far outweigh possible difficulties.

All infants under 12 months of age with confirmed HIV infection should be started on ART, irrespective of clinical or immunological stage. For children age 12 months or older, clinical or immunological thresholds should be used to identify those who need to start ART. Severely malnourished children should - prior to take ART - benefit from nutritional rehabilitation.

| Criteria to start ART |
|-----------------------|
| Age                   |
| Infants <12 months    | 12 months through 35 months | 36 months through 59 months | 5 years or over |
| CD4%                  | <20                           | <20                           | <15            |
| Absolute CD4*         | <750 mm$^3$                   | <350 mm$^3$                   | As in adults (<200 mm$^3$) |

The introduction of antiretroviral treatment (ART) in the mid-1990s led to a marked reduction in morbidity and mortality from HIV infection. In addition to improving quality of life and reducing AIDS related deaths, ART treatment has been recognized to prevent HIV transmission by reducing viral load (1). However, over time ART has been associated with an increasing number of metabolic abnormalities such as the
development of dyslipidemia, insulin resistance, and HIV lipodystrophy syndrome (HIV-LS). These metabolic changes are known to contribute for the development of cardiovascular disease (CVD) and diabetes mellitus (DM), representing a challenge in the treatment of HIV infection. Moreover, lipodystrophy body changes can jeopardize the quality of life of these patients, leading to low adherence to ART and subsequent virologic and clinical failure (2).

During the last decade, an increasing frequency of dyslipidemia has been observed among ART treated HIV-positive patients. The prevalence lays somewhere in between 20% and 50% including hypertriglyceridemia (40-80%) and high total cholesterol (10-50%), with at least one physical abnormality in approximately 50% of patients depending on the type of drug regimen used (3). It is reported that as high as 82.3% of first line ART and 76.9% pre-ART patients had at least one lipid profile abnormality (4).

Patients with human immunodeficiency virus (HIV) /acquired immunodeficiency syndrome (AIDS) frequently present alterations in lipid metabolism due to infection with HIV itself, including elevated serum concentrations of triglycerides and low levels of total cholesterol (5). The mechanisms responsible for lipid profile changes in HIV/AIDS infected patients are proven to be complex and to date are not fully understood but are probably multifactorial. It is suggested that various conditions and complex interactions involving the direct and indirect effects of antiretroviral medications and HIV infection itself have played a role in development of dyslipidemia (6). Lipid profile alterations in pre ART patients are associated to the host’s response to systemic inflammation and persistent viral infection mediated by various cytokines including tumor necrosis factor (TNF), interleukins, and the interferon’s secreted by active immune cells in the adipose tissue (7). Increased production of these cytokines and inflammatory responses enhance β-adrenergic stimulation of adipose tissue and thus advance adipose tissue lipolysis which in turn results in a secondary elevation in hepatic fatty acid levels, providing a stimulus for triglyceride synthesis and secretion as very-low-density lipoprotein (VLDL) particles (6).

Different ART classes and even individual agents within each drug class can have disparate effects on lipid profile alteration which may determine selection of ART regimens for initiations of treatment. However, most of the previous studies explored vigorously on the effect of old ART regimens like stavudine (d4T) in lipid metabolism, which are now almost excluded from the combination therapy. Still the effect of recently approved ART regimens like Tenofovir Disoproxil Fumarate (TDF) on lipid metabolism remains fully unexplained particularly in sub Saharan African where most of HIV patients live. In this region, where 8 to 71% of patients initiating ART die within the first year of treatment, apart from baseline CD4 count, viral load, and stage of the disease, dyslipidemia is thought to be one of the contributing variables to high AIDS-related mortality (8). In addition, patients in developing nation initiating ART may experience different rates and types of lipid abnormalities than patients in developed countries because of differences in genetic background, dietary intake, and lifestyle factors (9). A better understanding of the prevalence and patterns of lipid metabolic derangements at early stage in both HIV infected patients and those initiated ART could be important to identify potential interventions as well as additional clinical measurements that can be used to improve the care of HIV patients.

Methods and Materials

Selection of Patients
The study was conducted in the Dept. of Biochemistry and in collaboration with OBGY and Pediatrics Dept. at CCM Medical College Kachandur, Durg. Investigation was carried out in 70 patients ART treated group compared with 70 of naive group.

Study period and design
This study was done at Chandulal Chandrakar Memorial Medical College Kachandur, Durg. This is the largest and first private medical college in the CG state. A comparative cross sectional study design was used to assess the prevalence and patterns of lipid profile derangements among HIV patients receiving first line ART with respect to treatment naive groups at CCM Medical College from Sept. 2014 to December 2017.

Study populations
All adult HIV positive patients (≥18 years of age) visited CCM Medical College and Govt. ART center Durg from Sept. 2014 to December 2017, were our source population for cases and controls.

Cases were defined as adult HIV positive (≥18 years old) who had been on first line ART treatment continuously for at least six months duration and controls were HIV positive adults who were not yet receiving ART prior to time of data collection. Those who had started/changed first line ART treatment within less than six months’ time and those on 2nd line ART treatment (for cases), with known diabetics and cardiovascular disease, those using lipid lowering drugs, Pregnant/ breast feeding women, were excluded from the study.

First-line ART regimens
As defined by the WHO, regimens that included nucleoside reverse transcriptase inhibitors (NRTIs): 3TC, AZT, or d4T,
TDF, and nonnucleoside reverse transcriptase inhibitors (NNRTIs): NVP or EFV and or do not include PIs.

**Data collection procedure**
Clinical and demographic data collection: Information on sex, age, specific ART type in use, ART start date, duration of treatment, duration of HIV infection, BMI, relevant signs and symptoms and medications if any were collected by trained nurses using structured questionnaires and patients medical record.

Blood Sample Collection, Transport and Processing: Following a standard and safety collection procedure, about 5 ml fasting venous blood was taken from the patients and the control groups by clinical nurses and senior laboratory technologist. Sera were separated after centrifugation at 3000 rpm for 10 minutes, stored at -20°C and thawed just before analysis.

Laboratory investigations: Fasting serum samples were analyzed for total cholesterol (TC) (10), triglyceride (TG)

**Table no 1 show General characteristics of the study population**

| Characteristics                  | ART treated group (n=70) | ART naive group (n=70) |
|----------------------------------|--------------------------|------------------------|
| Age                              | 8.84± 6.32               | 13.8± 8.46             |
| Sex                              |                          |                        |
| Male                             | 23                       | 31                     |
| Female                           | 47                       | 39                     |
| Residence in town                | 29                       | 32                     |
| Residence in Rural               | 41                       | 38                     |
| < 18 underweight                 | 13                       | 10                     |
| 18-25 normal weight              | 48                       | 52                     |
| >25 overweight                   | 9                        | 8                      |
| Hypertension History             | 0                        | 0                      |

Lipid alterations in patients with HIV/AIDS caused by the infection itself had been reported before the implementation of ART. In this study we showed that, serum concentration of triglycerides, total cholesterol, LDL-c and VLDL-c were significantly increased and HDL-c were lower in HIV-seropositive patients receiving ART compared to ART naïve group controls. The finding of Nguemain NF and Fantoni M (14, 15) supports to our findings and shows the activity of HDL-c decreased found in group I. These alterations were detected in patients infected with different HIV-1 subtypes.

The concentration of HDL-c in group I patients were 29.85 ± 21.56 and in group II the activity were 40.37 ±23.56 but there is no significant difference found in both groups. Low serum concentrations of HDL-c can be used as a marker of chronic inflammatory activity. In a cohort study conducted in Spain, untreated HIV-infected patients presented low HDL-c levels, especially if they had already received antiretroviral therapy in the past. However, HDL-c levels were found to be low even in patients receiving ART presenting adequate viral suppression and immune reconstitution, a finding that suggests that inflammatory activity was not completely controlled (16).

There was statistically significant difference between the two groups for TC, TG, TC/HDL-c ratio and TG/HDL-c ratio. The TC/HDL-c ratio was > 5 in 6 (8.5%) of group II subjects and 19(27.1%) of group I with participants on ART being 4 times more likely to have higher TC/HDL-c ratio ≥5. A high triglyceride to HDL-C ratio (≥2.4), a strong indicator of the insulin resistance syndrome, was detected in 42.3% of group II participants and 60% of group I participants (p=0.04). There was no significant difference between the two groups on HDL-C<40 and LDL-C >130 found. Pefura Yone et al. also found higher prevalence of raised value of TC, LDL-c, TG, and TC/HDL-c ratio > 5 in participants taking AZT compared to those taking D4T, while the prevalence of HDL-c<40 was similar in both regimens (17).

On the basis of our study we concluded that the level of TG, TC, HDL-c and VLDL-c is high in HIV positive populations.
receiving first line ART (group I) as compared to ART naïve (group II). Considering that these altered lipid profiles can be an independent risk factors for coronary artery diseases and myocardial infarction, treatment with first-line ART may actually have potential risks for cardiovascular health of HIV positive people receiving ART. HIV-infected patients without ART presented lipid alterations associated with the infection itself, characterized by a decrease of total cholesterol, LDL-c, and HDL-c, and by an increase of triglyceride levels. In contrast, ART regimens promoted distinct alterations in the lipid metabolism of these patients.

References

[1] World AIDS Day Report 2011. Zero new HIV infection, zero discrimination, zero AIDS related deaths. UNAIDS, the Joint United Nations Programme on HIV; 2011.
[2] eccato MG, Bonolo PF, Souza Neto AI, Araújo FS, Freitas MI. Antiretroviral therapy-associated dyslipidemia in patients, a reference center in Brazil. See comment in PubMed Commons below Braz J Med Biol 2011; Res 44: 1177-1183.
[3] Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. See comment in PubMed Commons below Curr Atheroscler Rep 2011; 13: 51-56.
[4] Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study, AIDS Research and Therapy 2012; 9: 31.
[5] Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86: 27–31.
[6] Erdenbileg A, Alison S, Larb B. Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy-Associated Metabolic Disorders and Risk Factors for Cardiovascular Disease. Metab Syndr Relat Disord 2009; 7: 401-410.
[7] Silva EF, Bassichetto KC, Lewi DS. Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol 2009; 93: 113-118.
[8] Ngu JN, Heimburger DC, Arnett DK, Nyirenda CK, Potter D, et al. Fasting Triglyceride Concentrations Are Associated with Early Mortality Following Antiretroviral Therapy in Zambia, N Am J Med Sci (Boston) 2010; 3: 79-88.
[9] Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleve Clin J Med 2005; 72: 1113-1120.
[10] Allain C, Poon L, Richmond N. Enzymatic determination of total cholesterol Clin. Chem 20/4 (1974): 470-475.
[11] Werner M, Gabrielson DG, Eastman G. Ultra micro determination of serum TG by bioluminescent assay. Clin Chem 1981; 27: 268-71.
[12] Burnstein M.M, Miller G.J. Gidez L.I. Phosphotungstate Mg2+ precipitation method for HDL-cholesterol quantitation. jr. lipidres 1970; 11: 583.
[13] Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. ClinCherm.1972;18:499-502.
[14] Fantoni M, Autore C, Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann N Y Acad Sci. 2001;946:179–99.
[15] Ngouemaim NF, Mbuagbaw J, Nkoa T, et al. Serum lipid profile in highly active antiretroviral therapy naïve HIV-infected patients in Cameroon: a case-control study. HIn Med. 2010;11:353–9.
[16] Llibre JM, Domingo P, Palacios R, Pérez-Elías MJ, Sánchez-de la Rosa R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS. 2006; 20:1407–14.
[17] Pefura Yone EW, Betyoumin AF, Kennye AP et. al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Res 2011; 8: 33.

*Corresponding -
Dr. Omesh Khurana
Assistant Professor, Department of Pediatrics
CCM Medical College Kachandur, Durg.